MedTrace Logo

Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria

NCT03201939 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2025-06-26

Study results available
· View outcomes & findings →

Summary

In this study, the Investigators plan to determine the optimal means to prevent or slow the progression of kidney disease among genetically at-risk northern Nigerian HIV-infected adults. Based on data from studies of diabetic kidney disease that used medications that block the renin angiotensin aldosterone system (RAAS), we plan to evaluate whether or not RAAS inhibition (using a widely available medication that blocks RAAS) in HIV-infected adults produces similarly promising results.

Conditions

Interventions

OTHER

Placebo Oral Tablet

Comparator placebo (control arm)

DRUG

Lisinopril

ACE-inhibitor (lisinopril)(intervention arm

Sponsors & Collaborators

  • Aminu Kano Teaching Hospital

    collaborator OTHER

  • SAIC-Frederick, Inc.

    collaborator INDUSTRY

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • Vanderbilt University Medical Center

    lead OTHER

Principal Investigators

  • C. William Wester, MD, MPH · Vanderbilt University Medical Center

  • Muktar H. Aliyu, MD, DrPH · Vanderbilt University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2021-11-30
Completion
2025-02-01

Countries

  • Nigeria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03201939 on ClinicalTrials.gov